Arrowhead Pharmaceuticals, Inc. Common Stock Earnings Dividend

Arrowhead Pharmaceuticals, Inc. Common Stock’s revenue fell -86.41% since last year same period to $73.74Mn in the Q1 2026. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. Common Stock has generated -72.07% fall in its revenue since last 3-months.

Arrowhead Pharmaceuticals, Inc. Common Stock’s net profit fell -135.83% since last year same period to $-132.73Mn in the Q1 2026. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. Common Stock has generated -530.79% fall in its net profits since last 3-months.

Arrowhead Pharmaceuticals, Inc. Common Stock’s net profit margin fell -363.71% since last year same period to -180.01% in the Q1 2026. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. Common Stock has generated -1642.56% fall in its net profit margins since last 3-months.

Arrowhead Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -1.17 - a -5.41% fall from last quarter’s estimates.

Arrowhead Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -1.17.

Arrowhead Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) fell -133.82% since last year same period to -0.93 in the Q1 2026. This indicates that the Arrowhead Pharmaceuticals, Inc. Common Stock has generated -133.82% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Arrowhead Pharmaceuticals, Inc. Common Stock’s return on assets (ROA) stands at -0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Arrowhead Pharmaceuticals, Inc. Common Stock’s return on equity (ROE) stands at -0.42.